Non-Invasive Markers of Atrial Cardiomyopathy Predict Arrhythmia Recurrence Post-AF Ablation

Overview

This study compared non-invasive indicators of atrial cardiomyopathy (AtCM) with invasive left atrial low-voltage substrate (LA-LVS) mapping in 200 atrial fibrillation (AF) patients undergoing first-time pulmonary vein isolation (PVI). Several ECG and echocardiographic markers correlated with LA-LVS and predicted arrhythmia recurrence after ablation, supporting their clinical utility for risk stratification.

Background

Atrial cardiomyopathy is a key substrate for atrial fibrillation, promoting progression and increasing recurrence risk after ablation. Diagnosis currently relies on invasive electroanatomical mapping to identify left atrial low-voltage areas, limiting preprocedural risk assessment. Non-invasive surrogates such as 12-lead ECG, transthoracic echocardiography (TTE), and blood biomarkers have been proposed but lack systematic head-to-head validation against invasive mapping and clinical outcomes. This study addresses this gap by evaluating these markers in a large AF cohort undergoing PVI.

Data Highlights

Key Findings

• Non-invasive ECG markers such as prolonged amplified PWD (≥150 ms) and pathological P-wave terminal force in lead V1 correlate strongly with invasively measured LA-LVS extent.
• Increased left atrial volume index (LAVI) on TTE is associated with greater LA-LVS and reflects atrial remodeling consistent with AtCM.
• Patients with pathological non-invasive markers had higher rates of arrhythmia recurrence after first-time PVI.
• Blood biomarkers (high-sensitivity CRP and troponin T) showed less consistent correlation with LA-LVS and arrhythmia outcomes.
• Interatrial activation time measured invasively complements non-invasive markers but requires invasive mapping.
• Non-invasive markers provide practical surrogates for AtCM diagnosis and risk stratification prior to ablation.

Clinical Implications

Non-invasive ECG and echocardiographic parameters can effectively identify atrial cardiomyopathy and predict arrhythmia recurrence risk after AF ablation. Incorporating these markers into preprocedural evaluation may improve patient selection and guide personalized management strategies. Reliance on invasive mapping may be reduced by validated non-invasive surrogates, facilitating broader clinical application.

Conclusion

This study validates several non-invasive markers of atrial cardiomyopathy against invasive voltage mapping and demonstrates their prognostic value for arrhythmia recurrence post-PVI. These findings support integrating non-invasive assessments into routine clinical workflows for AF ablation candidates.

References

1. Goette et al. 2016 -- EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies
2. Kottkamp 2013 -- Atrial cardiomyopathy: pathophysiology and clinical implications
3. Kosiuk et al. 2017 -- Amplified P-wave duration predicts arrhythmia recurrence after AF ablation
4. Marrouche et al. 2014 -- Atrial fibrosis detected by MRI and AF ablation outcomes
5. Kosiuk et al. 2018 -- Left atrial low-voltage substrate and arrhythmia recurrence
6. Kamel et al. 2018 -- Atrial cardiomyopathy and stroke risk
7. Mahajan et al. 2015 -- Atrial cardiomyopathy and stroke risk independent of AF
8. EHRA/HRS/APHRS/SOLAECE consensus statements 2017/2020 -- Atrial cardiomyopathy definitions
9. Kosiuk et al. 2019 -- Non-invasive markers of atrial cardiomyopathy
10. Kottkamp et al. 2017 -- Electroanatomical mapping techniques